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Abstract Vascular integrity is fundamental to the for-
mation of mature blood vessels and depends on a func-
tional, quiescent endothelial monolayer. However, how
endothelial cells enter and maintain quiescence in the
presence of angiogenic factors is still poorly understood.
Here we identify the fibroblast growth factor (FGF)
antagonist Sprouty2 (Spry2) as a key player in mediating
endothelial quiescence and barrier integrity in mouse aortic
endothelial cells (MAECs): Spry2 knockout MAECs show
spindle-like shapes and are incapable of forming a func-
tional, impermeable endothelial monolayer in the presence
of FGF2. Whereas dense wild type cells exhibit contact
inhibition and stop to proliferate, Spry2 knockout MAECs
remain responsive to FGF2 and continue to proliferate even
at high cell densities. Importantly, the anti-proliferative
effect of Spry2 is absent in sparsely plated cells. This cell
density-dependent Spry2 function correlates with highly
increased Spry2 expression in confluent wild type MAECs.
Spry2 protein expression is barely detectable in single cells
but steadily increases in cells growing to high cell
densities, with hypoxia being one contributing factor. At
confluence, Spry2 expression correlates with intact cell–
cell contacts, whereas disruption of cell–cell contacts by
EGTA, TNFa and thrombin decreases Spry2 protein
expression. In confluent cells, high Spry2 levels correlate
with decreased extracellular signal-regulated kinase 1/2
(Erk1/2) phosphorylation. In contrast, dense Spry2
knockout MAECs exhibit enhanced signaling by Erk1/2.
Moreover, inhibiting Erk1/2 activity in Spry2 knockout
cells restores wild type cobblestone monolayer morphol-
ogy. This study thus reveals a novel Spry2 function, which
mediates endothelial contact inhibition and barrier
integrity.
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Introduction
During angiogenesis a concerted action of hypoxia and
growth factors including vascular endothelial growth factor
(VEGF) and fibroblast growth factors (FGFs) induces the
formation of endothelial tip cells and stalk cells, and pro-
motes vascular cell proliferation, cell migration, and lumen
formation [1–4]. Ultimately, these cells mature and stabi-
lize into new, functional blood vessels that are able to
control permeability and to supply the newly vascularized
areas with oxygen and nutrients. In this physiological state,
endothelial cells form a tight monolayer, resist apoptosis
and remain quiescent (defined as reversible cell growth/
proliferation arrest) even in the presence of angiogenic
factors [5, 6].
Endothelial cells in culture can display either an ‘‘acti-
vated’’ or a ‘‘quiescent’’ phenotype. The behavior of
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growing angiogenic (activated) cells is recapitulated by
endothelial cells growing in sparse culture in vitro (thinly
scattered cells), whereas a tight monolayer of cultured
endothelial cells that is arranged in a cobblestone mor-
phology is quiescent [5]. It has been suggested that several
surface molecules associated with adherens and tight
junctions mediate cell-contact inhibition (cells undergo
growth arrest when they come into contact with each other)
and vascular integrity through regulation of intracellular
signaling cascades and transcription [7]. Endothelial cells
mediate contact inhibition of growth in part by exiting cell
cycle in response to the inhibition of extracellular signal-
regulated kinase 1/2 (Erk1/2) activity, a major mitogen-
activated kinase (MAPK) downstream of FGF and other
angiogenic growth factors [8].
An important class of negative regulators of receptor
tyrosine kinase (RTK) dependent MAPK activation is the
Sprouty (Spry) family of proteins. In Drosophila, Sprouty
(dSpry) modulates trachea branching [9] by inhibiting the
RTK/Ras/Erk signaling downstream of different growth
factors [10]. Sprouty2 (Spry2), one of four mammalian
homologs, exhibits the highest sequence conservation
across species [11] and plays a comparable role to dSpry in
regulating the embryonic lung branching morphogenesis in
mammals [12]. Furthermore, Spry2 modulates MAPK-
signaling in embryogenesis [13, 14], organ development
[15], and angiogenesis in vivo and in vitro [16, 17]. Spry2
is therefore a potential candidate to mediate cell-contact
inhibition in endothelial cells.
Here, we have assessed the potential role of Spry2 in
cell-contact inhibition and the formation and maintenance
of the endothelial monolayer. We compared the ability of
primary Spry2 expressing (Spry2 fl/fl) and Spry2 knockout
(Spry2-/-) mouse aortic endothelial cells (MAECs) to
form a functional endothelial monolayer. Furthermore, we
analyzed Spry2 expression and Erk1/2 activity in MAECs
plated at defined cell densities. We were particularly
interested of how endothelial cells process signals arising
from increasing cell density to allow a switch from a
proliferative, migratory phenotype to a quiescent, imper-
meable monolayer.
Materials and methods
Cell culture and treatments
Mouse aortic endothelial cells (MAECs) were isolated from
aortae of C57BL/6 wild type male mice (MAECs #) or
Sprouty2 floxed female mice (Spry2 floxed MAECs $) as
described in a previous study [18]. Cells were used for
experiments up to passage 10. For all experiments in this
study, cell culture dishes were coated with 0.1 % gelatin
(Carl Roth GmbH, Karlsruhe, Germany) for 20 min at
37 C. Cells were maintained in growth media (GM)
[DMEM (Biochrom, Berlin, BW, Germany) complemented
with 1 or 10 % FCS, 1 % sodium pyruvate, 1 % non-
essential amino acids, and 1 % penicillin–streptomycin
(Invitrogen, Carlsbad, CA, USA)] in a humidified 5 % CO2-
air atmosphere at 37 C. Serum-free media (GM without
FCS) was used for starvation. Cell numbers were assessed
with a NucleoCounter NC-100TM (Chemometec, Allerød,
Denmark). MAECs were treated with one or more of the
following growth factors and inhibitors: FGF2 25 ng/ml
(R&D Systems, Minneapolis, MN, USA); EGTA 2.5 mM
(Merck, Billerica, MA, USA); Bapta-AM 10 lM (Invitro-
gen); TNFa 50 ng/ml (R&D Systems); thrombin 10 u/ml
(Sigma-Aldrich, St. Louis, MO, USA), and U0126 5 lM
(Promega, Madison, WI, USA). To create a hypoxic envi-
ronment, cells were placed in a hypoxia incubator (Hera Cell
150) (Thermo Fisher Scientific, Waltham, MA, USA) with
1 % oxygen for 24 h. Micrograph pictures of cells were
taken with a digital camera (F-viewXS) (Olympus, Ham-
burg, Germany) and an inverted microscope (1X71)
(Olympus). GFP expression was monitored by using a
U-LH100HG light source with a U-MWB2 filter (Olympus).
Generation of Spry2 knockout cells
We seeded 800,000 Spry2 floxed MAECs ($) on a 10 cm
culture dish. The next day, the media was removed and a
virus (100 MOI) that contained either Ade-CRE-GFP or
Ade-CMV-GFP (Vector Biolabs, Philadelphia, PA, USA)
was added in 3 ml of growth media to the cells. After 6 h,
the media was removed, replaced by 10 ml of normal
growth media, and then incubated at 37 C. Endothelial
cells expressed GFP the following day. Downregulation of
Spry2 was assessed by using qRT-PCR and Western blot.
Steps that involved handling viruses or virus-transfected
cells were undertaken in a level-2 biosafety hood (VSB 90)
(Skan, Allschwil, Basel, Switzerland) in a certified cell
culture laboratory.
mRNA extraction and quantitative real-time PCR
To isolate RNA from cells, cells were first harvested by
scraping with a cell scraper (BD, Franklin Lakes, NJ, USA)
and the RNA then isolated by using RNeasy kit (Qiagen,
Hilden, NRW, Germany) according to directions in the
manufacturer’s manual. The RNA was then reverse tran-
scribed to cDNA by using the Taqman Kit (Applied Bio-
systems, Foster City, CA, USA). The following primers
were used for qRT-PCR: Spry2-fwd (ATAATCCGAG
TGCAGCCTAAATC), Spry2-rev (CGCAGTCCTCACAC
CTGTAG), GAPDH-fwd (TGTGTCCGTCGTGGATCTGA),
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and GAPDH-rev (CCTGCTTCACCACCTTCTTGA).
The cDNA samples and the forward and reverse primers
for the endogenous control gene (GAPDH) and the target
gene (Spry2), together with SYBR green PCR master mix
(Applied Biosystems) were loaded on a 96-well PCR
reaction plate. Data was collected and normalized to
GAPDH by running the relative quantitation program with
the 7500 real time PCR system (Applied Biosystems).
Immunoblotting
To extract protein from the cells, cells were washed twice
with ice-cold PBS and then harvested by scraping with a
cell scraper (BD) into 1 ml of ice-cold PBS. The cell
suspension was collected and then centrifuged for 5 min at
14,000 rpm at 4 C. The pellet was re-suspended in RIPA
buffer that contained a complete mini protease inhibitor
(Roche, Basel, Switzerland) and a phosphatase inhibitor
cocktail 2 (Sigma-Aldrich) and then was lysed by using
liquid nitrogen in four freeze-and-thaw cycles. The sample
was centrifuged for 15 min at 14,000 rpm at 4 C. The
resulting supernatant was collected and the protein con-
centration measured by using a BCA protein assay kit
(Thermo Fisher Scientific). Equal amounts of protein were
separated by SDS-PAGE and then transferred to a nitro-
cellulose membrane (BA85) (Whatman, Maidstone, Kent,
UK) by using a semidry blotting procedure. Membranes
were blocked for 1 h at room temperature (RT) in TBS that
contained 5 % skim milk powder (Sigma-Aldrich), washed
once with TBS that contained 0.1 % tween (TBST) and
then incubated overnight at 4 C with one of the following
primary antibodies: rabbit anti Sprouty2 (H-120) 1:4,000
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); rabbit
anti Sprouty2 (ab50317) 1:1,000 (Abcam, Cambridge,
Cambs, UK); rabbit anti pospho-Erk1/2 (9102) 1:1,000,
and rabbit anti total-Erk1/2 (9102) 1:1,000 (Cell Signaling,
Danvers, MA, USA); rabbit anti Hif-1a (NB100-479)
1:1,000 (Novus Biologicals, Littleton, CO, USA); and
mouse anti b-Actin 1:10,000 (A-5441) (Sigma-Aldrich).
The next day, the membrane was washed three times in
TBST and incubated with a secondary antibody—goat anti
rabbit antibody HRP (7074) 1:5,000–1:20,000 (Cell Sig-
naling) or anti mouse HRP (7076) (1:80,000) (Cell Sig-
naling)—for 1 h at RT. After another wash step, a
chemiluminescent substrate that is used for the detection of
HRP (Thermo Fisher Scientific) was applied to the mem-
brane for 1 min. The signal was detected with CL-XPosure
film (Thermo Fisher Scientific), and the resulting bands
were quantified by using ImageJ (Wayne Rasband, NIH,
MD, USA).
Proliferation assay
Spry2 KO and Spry2 wilt type MAECs ($) were seeded at
the indicated densities in 8 replicates and grown in 100 ll
of growth media with 1 % FCS in a 96-well plate both with
and without 25 ng/ml of FGF2. After 48 h, 10 ll of ala-
marBlue solution (Invitrogen) was added for 3 h. Fluo-
rescence was measured (Ex 560; Em 590) by using a
Spectramax M2 reader (Molecular Devices, Sunnyvale,
CA, USA).
Permeability assay
The permeability assay was performed according to
directions in the manufacturer’s manual (Millipore, Bille-
rica, MA, USA). 200,000 Spry2 KO and Spry2 wild type
MAECs ($) were suspended in 200 ll of complete growth
medium supplemented with 1 % FCS and both with and
without 25 ng/ml of FGF2. The cells were then seeded in
triplicate on cell culture inserts (3-lm pore size) (Milli-
pore) and placed in 24-well culture plates (BD) that con-
tained 600 ll of FGF2-free medium per well. After 48 h,
the inserts were moved to a new 24-well plate and 70 kDa
FITC-dextran was added for 10 min. Fluorescence at Ex
585 nm and Em 520 nm of the lower well compartments
was analyzed by using a Spectramax M2 reader.
Oxygen sensing
Changes in the oxygen saturation of cell cultures were
measured in real time by using an SDR SensorDish reader
(Presens, Regensburg, BY, Germany). MAECs (#) were
plated on an Oxodish 24-well plate (OD24) with integrated
oxygen sensors (Presens). Oxygen saturation of the media
was measured every 30 min and data was collected and
analyzed by using SDR_v38 software (Presens) on a per-
sonal computer.
Electric cell-substrate impedance sensing (ECIS)
Electrical resistance measurements were performed using
an ECIS ZO– apparatus (Applied Biopyhysics, Troy, NY,
USA) in 8-well (0.8 cm2/well) arrays with 40 (8W10E ?)
gold electrodes, each with a diameter of 250 lm (Applied
Biopyhysics). Each experiment was carried out in dupli-
cate. Before seeding the cells, each well was pre-incubated
with serum-free DMEM overnight that was followed by a
20 min coating with 0.1 % gelatin (Carl Roth GmbH) and
0.9 % sodium chloride in PBS followed by three wash
steps with growth media. The arrays in the measurement
station were then placed in an incubator (37 C, 5 % CO2)
to allow real time monitoring. Total resistance was
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measured at a frequency of 4 kHz. Initial baseline values
were normalized to 1.
Statistical analysis
All statistical tests were performed by using GraphPad
Prism 5.04 for Windows (GraphPad software, San Diego,
CA, USA). We use unpaired t test to evaluate differences
between two groups. If there were more than two groups,
we used one-way ANOVA, followed by a Newman-Keuls
post-test. P \ 0.05 was considered significant.
Results
Lack of Spry2 expression results in loss of contact
inhibition and endothelial monolayer integrity
We generated Spry2 knockout MAECs (mouse aortic
endothelial cells) to explore whether Spry2 regulates the
formation of the endothelial monolayer and thereby
mediates cell-contact inhibition. Adenoviral transfection of
floxed-Spry2 MAECs with a Cre recombinase encoding
expression vector (Ade-CRE-GFP), but not with a control
vector (Ade-CMV-GFP), efficiently down-regulated Spry2
mRNA and protein levels (Fig. 1a–d).
Spry2-/- (knockout) and Spry2 fl/fl (wild type) MAECs
were then seeded at confluence in the presence or absence
of FGF2. We observed that Spry2-/- MAECs grown for
48 h in the presence of FGF2, were incapable of forming a
mature monolayer and displayed an elongated, angiogenic
phenotype with longitudinal gaps between the cells and
little cell–cell contacts (Fig. 2a2). In contrast to the latter
results, control Spry2 fl/fl MAECs formed a regular cob-
blestone-type cell monolayer with only a few elongated
cells (Fig. 2a1). FGF2 was required to disturb layer for-
mation in Spry2-/- MAECs, because without FGF2 stim-
ulation, Spry2-/- and Spry2 fl/fl cells both formed a regular
mature monolayer (Fig. 2a1, a2).
To further characterize the perturbed endothelial
monolayer formation by Spry2-/- cells, we analyzed
monolayer permeability. Indeed, the monolayer formed by
Spry2-/- cells exhibited significantly increased perme-
ability to a 70 kDa FITC-dextran in the presence of FGF2,
while no difference was observed in cells without FGF2
(Fig. 2b). Spry2-/- MAECs appear to fail in establishing
cell contact inhibition. We therefore asked, whether
Spry2-/- cells show increased cell proliferation. We then
plated the cells at different densities and let them grow for
48 h in the presence or absence of FGF2 before evaluating
the cell cumbers. No difference was observed between
Spry2-/- and Spry2 fl/fl when cells were plated at initially
sparse conditions (3,000 cells/cm2) (Fig. 2c). However,
when the cells were plated with a higher initial density
(6,000 and 12,000 cells/cm2), the cell numbers increased
significantly in Spry2-/- MAECs as compared to Spry2 fl/fl
MAECs after 48 h of FGF2 stimulation (Fig. 2c). No dif-
ference was observed between Spry2-/- and Spry2 fl/fl
when cells were grown without FGF2. These findings
indicate that Spry2 is indispensable for endothelial cell
monolayer formation and the maintenance of barrier
integrity in the presence of FGF2. Apparently, the function
of Spry2 thereby depends on an increased cell density.
High cell density induces Spry2 expression
Next we asked, whether the Spry2 function at high cell
densities correlated with increased Spry2 expression at
high cell densities. We therefore compared Spry2 protein
Fig. 1 Generation of Spry2 knockout MAECs a MAECs ($) were
isolated from floxed Spry2 female mice. The cells were then exposed
to Ade-Cre-GFP Adenovirus or the corresponding Adenovirus
without Cre. b GFP expression 24 h after transfection with either
Ade-Cre-GFP (Spry2-/-) or the corresponding control virus
Ade-CMV-GFP (Spry2 fl/fl) (scale bar 100 lm). c, d Efficient
knockout of Spry2 was confirmed by qRT-PCR analysis (error bars
show mean ± SEM; ***P \ 0.001; n = 3) (b) and immunoblotting
analysis (c). b-actin was used as loading control
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expression of cells, which were seeded at different densi-
ties (Fig. 3a). Sparsely plated cells (1,500–6,000 cells/cm2)
expressed Spry2 protein at very low levels. Subconfluently
plated cells (12,000–25,000 cells/cm2) increased Spry2
protein markedly. Plating 50,000 cells/cm2 led to the for-
mation of a confluent monolayer and a strong induction
Spry2 protein (Fig. 3b). We then analyzed the Spry2
mRNA expression of sparse (3,000 cells/cm2) and conflu-
ent cells (50,000 cells/cm2) and compared it to the
corresponding protein expression. Whereas the Spry2
protein levels increased 70 fold in confluent compared to
sparse cells, the mRNA levels increased only moderately
(two fold), suggesting that density dependent Spry2
expression is regulated predominantly at a post transcrip-
tional level (Fig. 3c).
To better understand the fashion of cell density-induced
Spry2 expression, we analyzed Spry2 protein expression
during formation of the endothelial monolayer. MAECs
Fig. 2 Spry2 knockout results in a loss of contact inhibition and
endothelial monolayer integrity (a1, a2). Micrographs (scale bar
100 lm) display Spry2 fl/fl (a1) and Spry2-/- (a2) MAECs ($) plated
at confluence and grown for 48 h in the presence of 1 % FCS both
with and without FGF2 (25 ng/ml). Magnifications (scale bar 50 lm)
of FGF2-treated Spry2 fl/fl and Spry2-/- cells are shown at the bottom
of the panel. b Modulation in monolayer permeability of Spry2 fl/fl
and Spry2-/- cells in the presence of FGF2. Cells were seeded at
confluence on a well insert in the presence of 1 % FCS with and
without FGF2 (25 ng/ml). The permeability of the monolayer to
70 kDa FITC-dextran after 10 min was evaluated by measuring
fluorescence of the lower well. Bars show values as fold change of
control ± SEM; ***P \ 0.001; n = 4. c Spry2-/- cells lack contact
inhibition. Cells were plated at the indicated cell densities and grown
for 48 h in the presence of 1 % FCS both with and without FGF2
(25 ng/ml). Bars show the FGF2-induced proliferation of Spry2 fl/fl
and Spry2-/- MAECs ($) normalized to the unstimulated cell at the
indicated plating densities ± SEM; ***P \ 0.001 versus 3,000 cells/
cm2 ? FGF2; ##P \ 0.01; ###P \ 0.001 Spry2 fl/fl versus Spry2-/-;
ns = non-significant; n = 3
Angiogenesis (2013) 16:455–468 459
123
were plated sparsely and grown to high cell density and
confluence over a time period of 24–96 h (Fig. 3d). Spry2
expression increased markedly after 48 h, and reached its
maximum level between 72 and 96 h after seeding
(Fig. 3e). Thus, Spry2 protein expression increased not
only when cells were plated at high cell density, but also
when cells grow from an initial sparse culture to a con-
fluent culture.
Hypoxia increases Spry2 expression during formation
of the endothelial monolayer
Conventional monolayer cultures are often hypoxic when
incubated in an air/5 % CO2 atmosphere [19]. Thus,
hypoxia that results from increased oxygen-consumption
during endothelial monolayer formation may correlate with
high cell density and may upregulate Spry2 expression. To
investigate this hypothesis, we analyzed the expression of
the hypoxia marker Hif-1a over a time period of 24–96 h.
Hif-1a levels increased at 48 h, dropped at 72 h, and were
undetectable after 96 h of cell seeding (Fig. 4a). We then
further substantiated these findings by measuring oxygen
levels of sparsely seeded cells directly and in real time over
a period of 0–96 h: Oxygen saturation decreased slightly
after 24 h (80 % O2 saturation) and declined to a minimum
between 48 and 72 h after cell seeding (70 % O2 saturation)
compared to a control with no cells present (85 %
O2 saturation throughout the experiment) (Fig. 4b). These
results demonstrate that increased Spry2 expression after
48 h of endothelial cells growing to confluence is accom-
panied by hypoxia and elevated Hif-1a expression.
To investigate whether hypoxia indeed induces Spry2
protein expression, we reduced oxygen consumption by
starving the cells to reduce metabolism [19]. Indeed, Spry2
protein levels decreased but were still detectable in starved
cells (Fig. 4c). In addition, Hif-1a protein levels dropped
and were undetectable after changing growth media to
serum-free conditions (Fig. 4c). In parallel experiments
replacement of the growth media by serum-free media after
24 h reduced the oxygen consumption of the endothelial
cell cultures and restored basal oxygen levels after 48 h.
However, in the presence of serum, oxygen levels
Fig. 3 High cell density
induces Spry2. a Representative
micrographs of MAECs (#)
plated at different cell numbers
(scale bar 100 lm). b MAECs
(#) were subjected to
immunoblotting after 24 h of
serum starvation. c mRNA
expression of sparse (3,000
cells/cm2) and confluent cells
(50,000 cells/cm2) was analyzed
by qRT-PCR and compared to
the corresponding protein
expression (Spry2/b-Actin) of
sparse and confluent cells
(MAECs #). The present graphs
summarize at least three
independent experiments. The
values shown are mean ± SEM;
**P \ 0.01; ***P \ 0.001
versus 3,000 cells/cm2. d,
e Cells (MAECs #) growing to
confluence increase Spry2.
d Micrographs (scale bar
100 lm) of MAECs plated at
sparse condition (3,000 cells/
cm2) and grown for the
indicated time. e Cell (MAECs
#) samples were collected at the
indicated times and Spry2 and
b-actin levels were analyzed by
immunoblotting
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decreased further and reached a minimum level (65 %
O2 saturation) after 48 h of cell seeding (Fig. 4d).
To assess whether endothelial cells cultured in serum-
free medium did not lose the potential to induce Spry2
expression under hypoxia, cells were seeded at sparse or
confluent density, and serum-free endothelial cells were
subjected to hypoxic (1 % O2) and normoxic conditions in
a hypoxia incubator. After 24 h, Spry2 increased in cells
under hypoxic conditions; this correlated with increased
Hif-1a protein levels (Fig. 4e). Hypoxia, however, did not
affect Spry2 mRNA levels (Fig. 4f). Thus, it is likely that
hypoxia regulates Spry2 expression independent of Hif-1a
on a post-transcriptional level.
Disruption of calcium dependent cell–cell contacts
decreases Spry2 protein in confluent cells
Although transient hypoxia induced Spry2 expression in the
early phase of endothelial cell monolayer formation, it
appeared that hypoxia was not necessary to maintain high
Fig. 4 Hypoxia increases Spry2 protein expression. a Cells (MAECs
#) growing to confluence become hypoxic. Cell samples were
collected at the indicated times and analyzed for Hif-1a and b-actin
protein expression. b Real-time measurement of the oxygen con-
sumption of MAECs (#) growing to confluence (initially plated at
sparse density; 3,000 cells/cm2). c Cells (MAECs #) were grown in
10 % FCS for 24 h and then either collected or starved for 24 h, and
then Spry2 levels were determined by immunoblotting. Three
independent experiments, normalized to b-actin expression, are
summarized in a graph that shows densitometric quantification of
the immunoblotting signals (**P \ 0.01). d In parallel experiments,
real time oxygen consumption of growing and quiescent cells
(MAECs (#) plated at confluence; 50,000 cells/cm2). After 24 h,
either serum free or media with 10 % FCS was added for additional
24 h to the cells (indicated with a dashed line). d MAECs (#) were
grown for 24 h and then starved and grown under either hypoxic (1 %
O2) or normoxic (21 % O2) conditions before lysis and immunoblot-
ting for Spry2, Hif-1a and b-actin. Three independent experiments,
normalized to b-actin expression, are summarized in a graph that
shows densitometric quantification of the bands (**P \ 0.01).
h mRNA was collected from MAECs (#) grown for 24 h and then
starved and grown under either hypoxic (1 % O2) or normoxic
(21 % O2) conditions and analyzed for Spry2 expression by
qRT-PCR. Values were normalized to GAPDH; n = 4
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Spry2 levels when the cells reached confluence (Figs. 3e,
4a). Therefore, we hypothesized that in confluent cells Spry2
might be stabilized at an elevated level through a hypoxia-
independent mechanism, including cell–cell contact.
To examine whether cell–cell contact regulates Spry2,
we used ethylene glycol tetraacetic acid (EGTA) to chelate
extracellular calcium and to disrupt calcium-dependent
cell–cell contacts [20]. The addition of EGTA to confluent
MAECs resulted in the formation of gaps between cells
after 30 min and in a complete detachment from each other
after 3 h (Fig. 5a). Replacement of EGTA with new media
restored the monolayer after 24 h of incubation. In parallel
experiments, treatment with EGTA completely eliminated
Spry2 expression after 0.5 and 3 h of EGTA treatment
(Fig. 5b). The restoration of the monolayer by new media
also restored Spry2 protein to the levels seen prior to
EGTA treatment. In addition, we measured the electrical
resistance of the confluent endothelial monolayer during
EGTA treatment by electrical cell impedance sensing
(ECIS). The electrical resistance dropped markedly after
Fig. 5 Disruption of cell–cell contacts decrease Spry2 protein levels.
(a, panels 1–3) Micrographs (scale bar 100 lm) of MAECs (#)
plated at confluence and treated with PBS (the control) or EGTA for
the indicated time. (a, panel 4) After 3 h, EGTA was replaced by
fresh growth media, and cells were grown for an additional 24 h.
b Spry2 expression after EGTA treatment. MAECs (#) were collected
after the indicated incubation time with PBS (control) or EGTA or
24 h after replacement of EGTA with fresh media (3.0 ? 24). c Cells
were plated at confluence, and total resistance was measured in real
time by ECIS. When cells reached a steady plateau in resistance
(baseline), either EGTA or PBS (control) was added to the cells. After
8 h, new media was added to all cells and the time point was set to
zero. d MAECs (#) were treated with either EGTA or BAPTA-AM
for 3 h, and Spry2 and b-actin expression were analyzed by
immunoblotting. e In parallel experiments, total RNA was isolated
from MAECs (#) that had been treated with EGTA, BAPTA-AM, or
PBS. Spry2 mRNA levels were determined by using qRT-PCR and
normalized to GAPDH. The values shown are mean ± SEM; n = 3.
f Spry2 protein expression 3 h after addition of either TNFa,
thrombin or PBS (control) to confluent cells. g Normalized resistance
of confluent cells treated with either TNFa, thrombin or PBS (control)
for the indicated time
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the addition of EGTA and then returned to basal levels
(resistance prior the addition of EGTA) within 48 h after
the addition of new media. This result demonstrated that
the effect of treatment with EGTA was reversible and did
not damage endothelial cell viability (Fig. 5c). Of note,
chelation of intracellular calcium with Bapta-AM did not
affect Spry2 protein levels (Fig. 5d), and neither EGTA nor
Bapta-AM affected Spry2 mRNA levels (Fig. 5e).
Our results indicate that high Spry2 protein levels
restrict endothelial permeability in confluent cells. Since
several physiologic conditions such as inflammation dis-
play and require increased monolayer permeability, we
asked whether Spry2 protein expression can be decreased
by physiological mediators of endothelial permeability
such as TNFa [21, 22] and thrombin [23]. Indeed, Spry2
protein expression decreased when confluent cells were
treated for 3 h with either TNFa or thrombin as compared
to the control cells (Fig. 5f). As control for the increased
permeability, we measured the change in total resistance of
cells after addition of either TNFa or thrombin. As
expected, the results showed a rapid disruption of the
endothelial barrier properties by thrombin with partial
recovery as compared to a rather chronic destabilization by
TNFa (Fig. 5g). Taken together, these findings demon-
strate that density-dependent Spry2 protein expression
depends on intact cell–cell contacts and is downregulated
by agents that increases endothelial permeability.
At high cell densities high Spry2 protein levels
correlate with decreased Erk1/2 phosphorylation
A well-established inhibitor of Erk1/2 activity downstream
of FGF signaling [17, 24] Spry2 might mediate cell-contact
inhibition in confluent cells via Erk1/2 inhibition. We
therefore compared Spry2 expression with Erk1/2 phos-
phorylation in sparse and confluent cells. In sparse cells,
FGF2-induced Erk1/2 phosphorylation levels were detec-
ted along with low Spry2 protein levels (Fig. 6a). Vice
versa, Spry2 was exclusively increased in confluent cells
and correlated with decreased Erk1/2 phosphorylation. In
the presence of FGF2, cell confluence significantly
decreased FGF2-induced Erk1/2 phosphorylation when
compared to sparse, FGF2-stimulated cells (Fig. 6a).
Taken together, these results suggest that cell density is
crucial to regulate Spry2 expression and by that its function
as an inhibitor of FGF2-Erk1/2 signaling.
Inhibition of Erk1/2 signaling restores wild type
morphology of the monolayer
Next we asked, whether Spry-/- MAECs exhibited
increased Erk1/2 phosphorylation. Indeed, in Spry2-/- cells,
FGF2-induced Erk1/2 phosphorylation levels increased 2.5
fold compared to those in Spry2 fl/fl cells, while Erk1/2
phosphorylation was absent without stimuli in both cell types
(Fig. 6c1, c2).
We therefore investigated whether inhibiting the MAPK
Erk1/2 pathway could reverse disturbed endothelial
monolayer formation of Spry2-/- cells. Spry2 fl/fl and
Spry2-/- MAECs were plated in the presence or absence
of the Erk1/2 inhibitor U0126. In the absence of U0126,
Spry2-/- MAECs showed a highly angiogenic phenotype
upon FGF2 stimulation. However, when cells were pre-
incubated with U0126 before adding FGF2, the wild type
cobblestone phenotype was restored (Fig. 6b). The absence
of Erk1/2 phosphorylation upon U0126-treatment in both
Spry2 fl/fl and Spry2-/- MAECs demonstrated the efficacy
of the Erk1/2 inhibitor (Fig. 6c1). Notably, upon inhibition
of Erk1/2 Spry2 expression was reduced in Spry2 fl/fl cells,
indicating that the expression of Spry2 is partly regulated
by Erk1/2 signaling. These findings show that Spry2, as a
regulator of Erk1/2 activity, is indispensable for endothelial
cell monolayer formation and the maintenance of barrier
integrity in the presence of FGF2.
Discussion
Cell-contact inhibition is an important process for the
regulation of vascular integrity for which proper under-
standing of underlying molecular events is still lacking.
This study therefore addresses the important question of
how endothelial cells process signals arising from
increasing cell density to allow a switch from a prolifera-
tive, migratory phenotype to a quiescent, impermeable
monolayer. Here, we identify the FGF receptor signaling
antagonist Spry2 as a key component in the establishment
of endothelial quiescence and barrier integrity.
Spry2 exclusively acts as an adaptor protein without any
enzymatic activity [25]. Therefore cells have restricted
possibilities to control Spry2 function: by regulating its
abundance [26–28], its localization [17, 29], and/or its
post-transcriptional modifications [30–32]. Here we show,
that in primary endothelial cells, Spry2 is regulated in a
previously unknown cell-density dependent fashion and is
found at high levels only in dense endothelial cell mono-
layers. Highly elevated Spry2 protein levels might inhibit
endothelial proliferation and, thus, maintain vascular
integrity and quiescence. Forced Spry2 expression in
human umbilical vein endothelial cells was shown to
inhibit growth factor-induced proliferation and sprouting
[17]. We here demonstrate that sparse cultures of prolif-
erating endothelial cells express low Spry2 protein levels
and that upon reaching cell confluence and cell quiescence
Spry2 protein levels increase by a mostly post-transcrip-
tional mechanism. Notably, ablation of Spry2 in dense cells
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increases cell proliferation and permeability of the endo-
thelial monolayer. Thus restriction of Spry2 may allow
endothelial cell proliferation and migration during angio-
genesis and wound closure [16, 33]. In accord with our
findings, Zhang et al. [34] showed that Spry2 protein
decreased in the vasculature after an injury to the endo-
thelial lining of the carotid artery in rats and then reap-
peared weeks later after the inner endothelial lining had
re-formed. We report that Spry2 protein levels increase
steadily in cells that are growing toward confluence. Two
independent and consecutive stimuli induce and stabilize
Spry2 protein levels—transient intrinsic hypoxia and the
establishment of cell–cell contacts. In the sub-confluent
phase, Spry2 expression correlates with reduced oxygen
saturation and increases Hif-1a protein levels. Further-
more, exogenously applied hypoxia increases Spry2 pro-
tein in both sparse (results not shown) and confluent cells
in post transcriptional manner. A possible explanation for
this finding is delivered by Anderson et al. [26]. They
showed that Spry2 interacts with prolyl hydroxylases
preferentially during normoxic conditions. When hydrox-
ylated on proline residues, Spry2 is recognized by pVHL
and its associated E3 ubiquitin ligase complex, resulting in
Spry2 degradation. Thus under hypoxic conditions, when
PDHs are less active, Spry2 levels increase [26].
In vivo, hypoxia-induced Spry2 expression may provide
a protective homeostatic function when the vasculature is
exposed to hypoxia. Endothelium that is subjected to
Fig. 6 Inhibition of Erk1/2 signaling restores wild type morphology
of the Spry2-/- monolayer. a High cell density-induced Spry2
correlates with decreased Erk1/2 phosphorylation. Sparse (3,000
cells/cm2) or confluent MAECs (#) (50,000 cells/cm2) were starved
and then treated with FGF2 (25 ng/ml) or PBS for 24 h before lysis
and immunoblotting. Relative phosphorylation levels of Erk1/2 were
quantified by densitometry. Bars show values as fold change of
unstimulated sparse cells ± SEM; **P \ 0.01; ***P \ 0.001; n = 3.
b Micrographs displaying Spry2 fl/fl and Spry2-/- MAECs ($) plated
at confluence in the absence or presence of FGF2 (25 ng/ml) and then
grown for 48 h. Where indicated, cells were incubated with U0126
(5 lM) 1 h prior the addition of FGF2 (scale bar 100 lm). c1
MAECs ($) were plated at confluence in the presence or absence of
FGF2 both with and without pre-incubation with U0126 (5 lM). Cells
were collected 4 h after seeding and phosphorylated Erk1/2
(p-Erk1/2), total Erk1/2 (t-Erk1/2), Spry2 and b-actin were analyzed
by immunoblotting. c2 Relative phosphorylation levels of Erk1/2
were quantified by densitometry. Bars show values as fold change of
FGF2-stimulated Spry2 fl/fl cells ± SEM; **P \ 0.01; n = 3
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oxygen deprivation maintains cell viability and basic bio-
synthetic mechanisms, but it displays multiple changes in
barrier function that are relevant to vascular homeostasis
[35, 36].
The observation that Spry2 expression still remains
elevated in confluent cells showing normoxic oxygen lev-
els points to another essential mechanism for stabilizing
Spry2 in confluent cultures: intact cell–cell contacts. An
intriguing question is how Spry2 is induced when cells
reach confluence. Possible membrane initiators of the
intracellular signals engaged by direct cell-to-cell contacts
are the N- and VE-cadherins. N- and VE-cadherins are
components of endothelial adherens junctions [37, 38] and
interact with cadherins of neighboring cells in a homophilic
manner [39]. These adhesive complexes strictly depend on
extracellular calcium [20, 40]. We show that Ca2? deple-
tion disrupts cell–cell contacts and rapidly destabilizes
Spry2 protein. Conversely, the formation of cell–cell con-
tacts stabilizes Spry2 protein even at a stage, at which an
impermeable endothelial barrier is not yet completely re-
established. Thus, singular cell–cell contacts may already
suffice to stabilize Spry2 protein levels. Consistent with
this notion, previous reports have indicated that cadherin
clustering induces signaling, and these events may stabilize
Spry2 levels, when cells first touch each other before
complete confluence is reached and junctions are fully
stabilized [41, 42]. Thus, our findings point to calcium
dependent cell–cell interactions which are needed for
Spry2 expression when cells grow to confluence, with the
final evidence of proof still to be elucidated in future. The
observation that TNFa and thrombin increase endothelial
permeability and at the same time, decrease Spry2
expression further add to the assumption that cell–cell
contact upregulate Spry2 protein expression. In situations
such as inflammation, the endothelial permeability needs to
be increased to allow transmigration of immune cells to
fight pathogens [43]. Since high Spry2 levels correlate with
decreased endothelial permeability, cells might be forced
to restrict Spry2 expression in confluent cells via physio-
logical agonists of endothelial permeability such as TNFa
and thrombin [21–23].
At high cell density, cell–cell contact inhibition promotes
the switch from an angiogenic and proliferative state to a
quiescent endothelial cell phenotype. It is assumed that
membrane proteins in addition to maintaining cell–cell
adhesion, also sense cell–cell interactions and transduce this
information to intracellular signaling cascades [5, 44]. In
endothelial cells for example, contact inhibition is mediated
in part through inhibition of Erk1/2 [8]. Spry2 is a well-
known feed-back loop inhibitor of RTK signaling and
modulates Erk1/2 activity in various settings [16]. Therefore,
we have hypothesized that Spry2, by inhibiting Erk1/2
activity, promotes cell contact inhibition in confluent
endothelial cells. Indeed, Spry2 expression correlates with
decreased Erk1/2 activity at high cell density. Vice versa,
ablation of Spry2 in confluent cells increases FGF2-induced
but not basal Erk1/2 signaling. As a result, Spry2-/- cells fail
to form a connected monolayer and exhibit a spindle-shaped
morphology with increased proliferation and monolayer
permeability in the presence of FGF2.
The inability of Spry2-/- cells to form a functional
monolayer is likely due to unrestricted FGF2-Erk1/2 sig-
naling because Erk1/2 inhibition in Spry2-/- cells restores
the wild type-like endothelial cobblestone phenotype. We
speculate that unrestricted FGF2-Erk1/2 signaling activates
Hif-1a-induced gene regulation: experimental evidence in
several studies has demonstrated that FGF2 activates the
VEGF/VEGFR system [45, 46] in part via Hif-1a [47–49].
Whereas fine-tuned intracellular VEGF-A/VEGFR-2 sig-
naling supports endothelial survival in established mature
blood vessels [50], uncontrolled expression of VEGF-A
exceeding physiological thresholds leads to the formation
of unstable and leaky blood vessels [51] or even heman-
giomas [52]. Spry2 could potentially interfere with this
signaling cascade and prevent activation of the VEGF/
VEGFR system by FGF in quiescent blood vessels.
Spry2 knockout animals display discrete developmental
defects that have been attributed to unrestricted FGF sig-
naling [53–56]. Although we observe that Spry2 knockout
markedly affected endothelial quiescence and integrity
in vitro, Spry2 knockout mice seem to exhibit rather mild
malformations without an overt vascular phenotype. This
discrepancy might be due to redundancies amongst the
Sprouty isoforms in in vivo models. Furthermore, exposi-
tion of the knockout animals to stress, such as severe
hypoxia or high doses of growth factors, might reveal
additional Spry2-specific phenotypes.
FGF signaling has been identified as a strong pro-
angiogenic factor in physiological [4] and pathological
situations [57]. Murakami et al. [58] have demonstrated,
however, that it also plays a key role in the maintenance of
vascular integrity, because disrupted FGF signaling results
in severe impairment of the endothelial barrier function and
eventually to a disintegration of the vasculature. Therefore,
we propose that Spry2, by controlling Erk1/2 signaling,
switches the response of endothelial cells to FGF2 from
proliferation and migration to survival and quiescence
(Fig. 7).
In conclusion, the data of the present study show for the
first time that high Spry2 expression levels play a critical
role in endothelial monolayer formation and stabilization
by inhibiting FGF2-induced Erk1/2 signaling. This nega-
tive feedback loop may be important in situations, where
endothelial monolayers form, where the regulation of basal
permeability must be strict, and where vascular integrity
and quiescence must be established and maintained in vivo.
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For example, endothelial Spry2 expression might prevent
damage to the blood–brain barrier and the development of
vasogenic brain edema under prolonged hypoxia at high
altitude [59] or may promote vessel normalization by
inhibiting extensive growth-factor signaling in cancer [60].
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